Sleep restriction alters plasma endocannabinoids concentrations before but not after exercise in humans  by Cedernaes, Jonathan et al.
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a  b  s  t  r  a  c  t
Following  binding  to cannabinoid  receptors,  endocannabinoids  regulate  a variety  of  central  nervous  sys-
tem processes  including  appetite  and  mood.  Recent  evidence  suggests  that the  systemic  release  of  these
lipid  metabolites  can  be altered  by acute  exercise  and  that  their  levels  also  vary  across  the  24-h  sleep-
wake  cycle.  The  present  study  utilized  a within-subject  design  (involving  16  normal-weight  men)  to
determine  whether  daytime  circulating  endocannabinoid  concentrations  differ  following  three  nights  of
partial  sleep  deprivation  (4.25-h  sleep  opportunity,  2:45–7  a.m.  each  night)  vs. normal  sleep  (8.5-h  sleep
opportunity,  10:30  p.m.–7  a.m.  each  night),  before  and after  an acute  bout  of  ergometer  cycling  in the
morning.  In addition,  subjective  hunger  and  stress  were  measured.  Pre-exercise  plasma  concentrations
of  2-arachidonoylglycerol  (2AG)  were  80%  higher  1.5 h after  awakening  (vs. normal  sleep,  p  < 0.05)  when
participants  were  sleep-deprived.  This  coincided  with  increased  hunger  ratings  (+25%  vs.  normal  sleep,
p <  0.05).  Moreover,  plasma  2AG  was  elevated  15  min  post-exercise  (+44%,  p < 0.05).  Sleep  duration  did
not however  modulate  this  exercise-induced  rise.  Finally,  subjective  stress  was  generally  lower  on  the  day
after  three  nights  of short  sleep  vs. normal  sleep,  especially  after  exercise  (p  <  0.05).  Given that  activation
of  the endocannabinoid  system  has  been  previously  shown  to acutely  increase  appetite  and  mood,  our
results  could  suggest  that  behavioral  effects  of acute  sleep  loss,  such  as  increased  hunger  and  transiently
improved  psychological  state,  may  partially  result  from  activation  of  this  signaling  pathway.  In contrast,
more  pronounced  exercise-induced  elevations  of  endocannabinoids  appear  to  be less  affected  by short
sleep  duration.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd. This  is an open  access  article  under  the  CC  BY-NC-ND. Introduction
The endocannabinoids anandamide (AEA) and 2-
rachidonoylglycerol (2AG) are endogenously produced lipids
hat have been found, for instance, to be elevated in blood in
esponse to psychological stress (Hill et al., 2009; Dlugos et al.,
012). Due to their highly lipophilic properties, endocannabinoids
an readily cross the blood–brain barrier. Following their binding
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usargatan 3, Box 593, 751 24 Uppsala, Sweden.
E-mail addresses: jonathan.cedernaes@neuro.uu.se (J. Cedernaes),
hristian.benedict@neuro.uu.se (C. Benedict).
ttp://dx.doi.org/10.1016/j.psyneuen.2016.09.014
306-4530/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
to central nervous system receptors (e.g. CB1 receptors), endo-
cannabinoids have been shown, e.g., to reduce anxiety (Marsicano
et al., 2002; Lutz et al., 2015) and increase food intake (Di Marzo
et al., 2001). In relation to the latter, recent ﬁndings suggest
2AG to be more linked to hedonic motivation for food whereas
AEA seems to be more involved in driving homeostatic eating
(Monteleone et al., 2016). Remarkably, the aforementioned effects
of endocannabinoids resonate with those of sleep restriction, an
increasingly prevalent stressor in modern society (Ford et al.,
2015). Acute sleep loss increases food intake and ideal portion
sizes (Hogenkamp et al., 2013; St-Onge et al., 2011), accentuates
the brain’s hedonic response to food (Benedict et al., 2012), and
relatedly, impairs the ability to cognitively inhibit pre-potent
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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esponses to rewarding food stimuli (Cedernaes et al., 2014; topics
eviewed in Cedernaes et al., 2015a). Moreover, similar to the
nxiolytic effects of endocannabinoids, acute sleep deprivation
as repeatedly been shown to acutely alleviate symptoms of
epression (Wu et al., 1999). However, to date, only two  studies
ave been able to link systemic release of plasma concentrations
f endocannabinoids to acute sleep loss in humans (Hanlon et al.,
016; Vaughn et al., 2010), and have not tested how further
hysiological stress impacts this signaling system.
Another stressor that has been shown to activate the endo-
annabinoid system is physical exercise (Dietrich and McDaniel,
004). For instance, a recent study involving 11 healthy trained
ale cyclists found plasma AEA concentrations to be increased dur-
ng and shortly after intense exercise (i.e., 60 min  at 55% followed
y 30 min  at 75% Wmax; Heyman et al., 2012). In another study,
readmill running resulted in increased blood levels of AEA; how-
ver, only at moderate – versus low or high – exercise intensity (i.e.,
t 70–85% of age-adjusted maximum heart rate) (Raichlen et al.,
013). Finally, a study involving 24 young males demonstrated that
 h of moderate intensity exercise increased plasma AEA concen-
rations. In the same study, plasma 2AG concentrations showed a
imilar trend to increase following exercise, but failed to reach sta-
istical signiﬁcance (Sparling et al., 2003). To our best knowledge,
o study has yet investigated whether exercise-induced elevations
f endocannabinoids are affected by short sleep duration. Exercise-
nduced elevations of endocannabinoid levels have been proposed
o account partially for anxiolytic (Tantimonaco et al., 2014; Fuss
t al., 2015), anti-nociceptive (Galdino et al., 2014) and neuro-
rotective (Hill et al., 2010a) properties of exercise, which are all
esponses that instead are affected in a negative direction by sleep
oss (e.g. Roy-Byrne et al., 1986; Schuh-Hofer et al., 2013; Cedernaes
t al., 2016).
Against this background, the present study, involving 16 healthy
ormal-weight men, sought to determine whether short sleep
s. normal sleep duration would alter circulating levels of differ-
nt endocannabinoid species, before and after an acute bout of
rgometer cycling. In addition, subjective stress and hunger ratings
ere measured. Given that increased systemic release of plasma
oncentrations of endocannabinoids has recently been linked to
cute sleep loss, we expected recurrent sleep loss to alter plasma
ndocannabinoid concentrations. Moreover, we hypothesized that
xercise would transiently increase plasma endocannabinoid con-
entrations.
. Material and methods
.1. Participants
Sixteen male non-smokers were included in the present study
age: 22.9 ± 0.66 years; BMI: 22.9 ± 0.46 kg/m2]. An anamnestic
nterview by a medical doctor (J.C.) before study inclusion ensured
hat participants were in general good health (also veriﬁed by
linical blood parameters, e.g. white blood cell count), not on
edication, and that none of them reported to have been ever
een diagnosed with or treated for a psychiatric condition. This
valuation included general questions regarding current and
rior depressive, anxiety or other psychiatric symptoms, hered-
ty, as well as possible current or prior use of medications or
ietary/pharmaceutical supplements, including speciﬁc questions
bout psychiatric medications. Answers were also conﬁrmed and
urther elaborated during an anamnestic interview prior to study
nclusion (conducted by J.C.). Only subjects who stated during
creening that they habitually go to bed between 10 p.m. and
2 p.m., and who slept 7–9 sleep hours per night, were included
n the present study.crinology 74 (2016) 258–268 259
All participants provided written informed consent. The study
was conducted in accordance with the Helsinki Declaration and was
approved by the Regional Ethical Review Board in Uppsala (EPN
2014/242/1).
2.2. Experimental procedure
The study was based on a within-subject design, meaning that
all participants took part in two separate experimental conditions
(normal sleep vs.  short sleep duration), each of which lasted four
consecutive days and three nights (day and night 1; day and night
2; day and night 3; day 4) in our sleep laboratories at Uppsala Uni-
versity. The order of experimental conditions was randomized and
counterbalanced across subjects (Fig. 1).
In each experimental condition, upon arrival at 5:30 p.m. on
the baseline day (day 1), participants were provided with a
standardized dinner (8 p.m.), and were then prepared for sleep
polysomnography. In the normal sleep condition, participants were
given an 8.5-h sleep opportunity (10:30 p.m.–7 a.m.) on each exper-
imental day. In the short sleep condition, sleep was allowed for
4.25 h each night (2:45–7 a.m.) on experimental days, with lights
kept below 6 lx at eye level between 10:30 p.m. and 2:45 a.m..
During all experimental wake periods, i.e.,  when sleep was not
scheduled, participants were allowed to spend their time with
a selection of movies, games, and books, and they were contin-
uously monitored by experimenters. On each experimental day,
participants were provided with standardized meals, but were only
allowed to drink water (see Fig. 1). The sum of calories provided by
all meals on each experimental day (except for the ﬁrst day where
participants arrived in the late afternoon) corresponded to individ-
ual energy requirements (based on the Harris-Benedict equation
factored 1.2 for light physical activity; calories on the ﬁrst day cor-
responded to 33% of this calculated requirement). Participants were
also provided with three supervised scheduled walks on day 2 and
day 3 (daily total duration 60 min); otherwise they were conﬁned
to their rooms and could engage in sedentary-level activities. On
day 4 (i.e., after 3 nights of either short or normal sleep), partici-
pants were kept fasted, enabling the investigation of the inﬂuence
of sleep duration on fasting circulating concentrations of endo-
cannabinoids, both before and after acute exercise (see Section
2.3).
On the day of the exercise intervention (day 4), self-reported
hunger and stress were measured by means of a 100-mm visual
analogue scale (with 0 representing “Not hungry at all”/“Not
stressed at all” and 100 mm representing “Very hungry”/“Very
stressed”) at the following time points: 8:30 a.m., ∼10 a.m.,
∼11 a.m., and ∼3 p.m.
2.3. Exercise protocol
Exercise intensity was  calculated prior to the ﬁrst experimental
session for each individual by using a step-wise increasing ergome-
ter evaluation test (the Åstrands-Ryhming nomogram method,
with age-adjusting correction factors; Cink and Thomas, 1981).
Based on the relationship between workload (in Watts), and heart
rate and oxygen consumption, obtained during this test, the VO2
reserve capacity was  calculated (which, in contrast to VO2 max,
to a greater extent takes into account an individual’s resting oxy-
gen consumption level, and also corresponds more closely to heart
rate reserve, another measure of exercise intensity; Swain and
Leutholtz, 1997). The value of 75% of the VO2 reserve capacity
was then converted to a corresponding workload value (in Watts),
which was used for subsequent exercise tests on the same ergome-
ter. The ergometer evaluation test took place 1–2 weeks before the
ﬁrst session, and all ergometer tests were carried out on a standard
stationary ergometer (Lode Corival, Intramedic).
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The exercise protocol during the short and normal sleep condi-
ions was 35 min  long, and consisted of a 5-min warm-up period
t 25% of the subsequent workload. The higher workload cor-
esponded to 75% of VO2 reserve (average 177 ± 10 W)  and was
aintained for 30 min  after the warm-up period. Preceding to as
ell as after this exercise protocol on day 4, participants were
ed-restricted and could only engage in sedentary activities.
.4. Determination of plasma concentrations of
ndocannabinoids
Blood samples were taken from an intravenously placed
atheter at ﬁve different time points: day 3 at 7:30 p.m.; day 4
t 8:30 a.m., ∼10 a.m., (followed by the 35-min exercise proto-
ol), ∼15 min  and ∼4 h after the end of the exercise protocol.
mmediately after sampling with EDTA collection tubes, blood was
entrifuged (4 ◦C, 10 min, 1300g), plasma was removed and then
rozen at −80 ◦C.
Plasma levels of 2AG and AEA, and of the two AEA congeners [N-
leoylethanolamine (OEA) and N-palmitoylethanolamine (PEA)]
ere measured according to a previously described method (Fanelli
t al., 2012) from 250-l plasma samples. Given that 2AG is chem-
cally unstable and undergoes rapid isomerization to 1AG, we  also
easured concentrations of 1AG. The sum of 1AG and 2AG washerefore used as a measure of biological 2AG levels in the present
tudy.
Samples were rapidly thawed and spiked with deuterated inter-
al standards before being extracted with 2 ml  of toluene (Carlo partial sleep deprivation condition; wks, weeks; n = number of subjects.
Erba RS HPLC grade, Rodano, Italy). After a 10-min vortex and cen-
trifugation (4 ◦C, 10 min, 2000g), samples were dipped for 5 min
into methanol that had been bath cooled with dry ice. The upper
layer was transferred to 12 × 75 mm Pyrex tubes (Bibby Scien-
tiﬁc, Riozzo di Cerro, Italy) and dried under a nitrogen stream.
Samples were reconstituted with 100 l MeOH, and 70 l of the
resulting solution was  injected into the LC–MS/MS system, com-
posed of an HPLC Series 200 (PerkinElmer, Waltham, USA) and of
an API 4000 QTrap instrument (AB-Sciex, Toronto, Canada). Sam-
ples underwent on-line puriﬁcation on a perfusion column (POROS
R1/20 2.1 × 30 mm,  Applied Biosystems, Foster City, CA), separa-
tion by an analytical Discovery HS C18 3 m 7.5 × 4.6 mm column
(Supelco, Bellafonte, PA) and detection by atmospheric pressure
chemical ionization and multiple reaction monitoring mode. Quan-
titative and qualitative transitions were recorded for each analyte
in order to ensure speciﬁcity. The assay functional sensitivity in
plasma matrix was  0.039 pmol/ml for AEA, 0.156 pmol/ml for 2AG
and 1AG, and 0.390 pmol/ml for PEA and OEA.
As previously described (Fanelli et al., 2012), endocannabinoids
levels in blood or plasma undergo a rapid increase in a time-
dependent manner, possibly because they are released by blood
cells (AEA, PEA and OEA) or derived by lipid metabolism (2AG and
1AG). In order to minimize the analytical variability caused by this
phenomenon, samples from the same subject were processed in
the same batch, and each batch included two  replicates of low
and high level quality controls (QCs). Low level QCs were obtained
by pooling plasma samples derived by rapid blood processing
and storage, so that low physiologic endocannabinoids concentra-
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ions were preserved. Conversely, high level QCs were obtained by
ooling discarded plasma samples kept at 4 ◦C for 48 h, thus con-
aining increased endocannabinoids levels. Each QC was  parted in
ultiple individual aliquots. In each analytical batch, QC aliquots
ere strictly defrosted and processed as unknown samples. Intra-
atch, intra-assay and inter-assay imprecision was, respectively,
.5–11.2%, 2.0–13.9% and 0.6–17.1% for all analytes at low and high
evel.
.5. Sleep assessment
Prior to the ﬁrst experimental session, participants had an
vernight polysomnography in our sleep laboratory to reduce pos-
ible bias from the ﬁrst-night-effect on sleep maintenance and
uality in subsequent experimental nights (see also Tamaki et al.,
016). Participants were considered eligible for inclusion into the
resent study only if sleep parameters during their adaption night
ere within the standard range (e.g. sleep onset latency less than
0 min). The anamnestic interview prior to study inclusion further
nsured that none of the participants reported regular snoring, nor
id they report regular excessive daytime sleepiness, and ﬁnally,
hey had never been diagnosed with any sleep disorder or psy-
hiatric disorder. However, sleep polysomnography during the
daption night was not performed with e.g. respiratory recordings.
hus, although unlikely, we cannot completely rule out the pos-
ibility that some of our participants may  have suffered from e.g.
leep disorder breathing, although the likelihood thereof is further
educed by the fact that we only studied normal-weight, young and
ealthy participants.
During experiments, sleep was measured by Embla A10
ecorders (Flaga hf, Reykjavik, Iceland). EEG signals were derived
rom C3, C4, Fp1, Fp2 and referenced to the contralateral mastoid.
leep was subsequently scored by an experienced scorer (J.E.B.)
ccording to standard criteria (Silber et al., 2007).
.6. Statistical analysis
Repeated measures ANOVA was conducted to investigate our
wo main study aims: (a) the inﬂuence of recurrent short sleep
uration on fasting circulating concentrations of endocannabinoids
within-subject factors: Sleep condition and Pre/Post-sleep → day 3:
:30 p.m., day 4: 8:30 a.m.) and (b) whether recurrent short sleep
uration would alter the effects of acute physical exercise on circu-
ating concentrations of endocannabinoids (within-subject factors:
leep condition and Exercise time point → day 4: ∼10 a.m. (last pre-
xercise time point), as well as 15 min  and 4 h post-exercise).
oreover, a repeated measures ANOVA was utilized to investigate
c) the effects of recurrent partial sleep loss vs.  normal sleep on sub-
ective hunger and stress ratings on day 4 (within-subject factors:
leep condition and Time on day 4: 8:30 a.m., ∼10 a.m., ∼11 a.m., and
3 p.m.). The Greenhouse–Geisser method was used to correct for
phericity deviations. Pearson’s correlation analysis was utilized
o examine putative relationships between circulating concentra-
ions of endocannabinoids and rating scores at timepoints with
oinciding blood measurements and subjective ratings of hunger
nd stress.
Overall, two-tailed p-values below 0.05 were considered signif-
cant. Data are presented as means ± standard error of the mean
SEM), unless otherwise stated.
. Results.1. Sleep
A sleep diary that was kept by the participants conﬁrmed that
verage self-reported sleep duration in the week before the start ofcrinology 74 (2016) 258–268 261
each experimental session did not differ between the short and nor-
mal  sleep conditions (range 7–9 h per night; p > 0.10, as determined
by a paired t-test).
In the normal sleep condition (i.e., where subjects could sleep
for 8.5 h each night), the polysomnographic analysis revealed that
subjects slept in total 7.95 ± 0.13 h on the ﬁrst night, 7.91 ± 0.10 h
on the second night, and 8.02 ± 0.10 h on the third night. In the
short sleep condition (i.e., subjects had an sleep opportunity of
4.25 h each night), they slept in total 3.97 ± 0.05 h on the ﬁrst night,
4.07 ± 0.03 h on the second night, and 4.12 ± 0.02 h on the third
night (F(1,12) = 3495, p < 0.001 for the main effect of Sleep condi-
tion).
3.2. Daytime variations of plasma concentrations of
endocannabinoids
When considering all time points collected in the present
study (i.e., day 3: 7:30 p.m., day 4: 8:30 a.m., 10 a.m., as well as
15 min  (∼11 a.m.) and 4 h post-exercise (∼3 p.m.)) across both
sleep conditions, repeated measures ANOVA revealed a strong
main effect of time on plasma concentrations of 2AG (p < 0.001,
lowest concentration at 10 a.m. on day 4, 2.04 ± 0.16 pmol/ml;
highest concentration at 8:30 a.m. on day 4, 3.10 ± 0.44 pmol/ml),
AEA (p < 0.001, lowest concentration at 8:30 a.m. on day 4,
0.82 ± 0.04 pmol/ml; highest concentration at 7:30 p.m. on day
3, 1.16 ± 0.06 pmol/ml), PEA (p < 0.001, lowest concentration at
8:30 a.m. on day 4, 14.48 ± 0.53 pmol/ml; highest concentration at
∼3 p.m. on day 4, 18.58 ± 0.68 pmol/ml), and OEA (p < 0.001, lowest
concentration at 8:30 a.m. on day 4, 5.18 ± 0.26 pmol/ml; highest
concentration at ∼3 p.m. on day 4, 7.42 ± 0.33 pmol/ml).
3.3. Effects of nocturnal sleep duration on plasma concentrations
of endocannabinoids
A detailed summary of repeated measures ANOVA main and
interaction effects of within-subject factors Sleep condition and
Pre/Post-sleep,  or Exercise time point, on plasma endocannabinoid
concentrations is shown in Table 1.
3.3.1. Plasma concentrations of endocannabinoids before exercise
In the morning of day 4 (i.e., at 8:30 a.m. following 3 exper-
imental nights), plasma concentrations of 2AG were on average
+80% higher in the short vs.  normal sleep condition (3.99 ± 0.74
vs. 2.22 ± 0.21 pmol/ml, df = 15, t = 2.78, p = 0.014; Fig. 2A). No
differences were, however, observed in the evening of day 3 (i.e.,  fol-
lowing 2 experimental nights) between sleep conditions (p = 0.830,
pairwise t-test comparison; Fig. 2A).
Plasma concentrations of AEA, PEA, and OEA did not differ
between the sleep conditions (p ≥ 0.937 for all main effects of Sleep
condition; p ≥ 0.423 for all interaction effects of Sleep condition with
Pre/Post-sleep; Table 1 & Fig. 2B–D). In contrast, signiﬁcant main
effects of Pre/Post-sleep on plasma concentrations of AEA and PEA
were found, as morning values of day 4 were lower than those mea-
sured in the evening before (Table 1 & Fig. 2B,C). No such main
effects of Pre/Post-sleep were, however, observed for plasma con-
centrations of OEA (p = 0.263, Table 1 & Fig. 2D).
3.3.2. Effects of sleep duration on plasma concentrations of
endocannabinoids following exercise
As summarized in Table 1, repeated measures ANOVA revealed
neither main effects of Sleep condition nor interaction effects
of Sleep condition with Exercise time point on plasma concen-
trations of 2AG, AEA, PEA, and OEA (see also Fig. 3A–D). In
contrast, main effects of Exercise time point on plasma concen-
trations of 2AG and OEA were found (p ≤ 0.036 for all main
effects of Exercise time point; Table 1). Post-hoc comparisons
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Table 1
Repeated measures ANOVA main and interaction effects on plasma endocannabinoid concentrations across sleep conditions and before and after exercise.
EC Within-subject factors Interaction
Before exercise
Sleep condition P Pre/Post-sleep P Sleep condition * Pre/Post-sleep P
2AG F(1.0,15.0) = 4.12 0.060 F(1,15) = 0.27 0.610 F(1.0,15.0) = 7.56 0.015
AEA  F(1.0,15.0) = 0.0004 0.984 F(1,15) = 31.91 0.00005 F(1.0,15.0) = 0.68 0.423
PEA  F(1.0,15.0) = 0.006 0.941 F(1,15) = 6.77 0.020 F(1.0,15.0) = 0.06 0.810
OEA  F(1.0,15.0) = 0.007 0.937 F(1,15) = 1.35 0.263 F(1.0,15.0) = 0.009 0.924
EC  Within-subject factors Interaction
Following exercise
Sleep condition P Exercise time point P Sleep condition * Exercise time point P
2AG F(1.0,15.0) = 0.55 0.472 F(1.22,18.36) = 8.05 0.008 F(1.28,19.19) = 7.56 0.280
AEA  F(1.0,15.0) = 0.47 0.502 F(1.80,27.06) = 31.91 0.332 F(1.54,23.13) = 0.68 0.406
PEA  F(1.0,15.0) = 0.60 0.452 F(1.59,23.91) = 3.45 0.058 F(1.63,24.47) = 2.05 0.157
OEA  F(1.0,15.0) = 0.28 0.605 F(1.48,22.27) = 4.30 0.036 F(1.49,22.32) = 1.43 0.256
Repeated measures ANOVA was conducted to investigate the inﬂuence of recurrent short sleep duration on fasting circulating concentrations of endocannabinoids (within-
subject factors: Sleep condition and Pre/Post-sleep → day 3: 7:30 p.m., day 4: 8:30 a.m.) and whether recurrent short sleep duration would alter the effects of acute physical
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s  well as 15 min  and 4 h post-exercise). The Greenhouse-Geisser method was use
nandamide; EC, endocannabinoid; PEA, palmitoylethanolamide; OEA, oleoylethan
evealed that plasma concentrations of 2AG were only signiﬁ-
antly different when pre-exercise and 15 min  post-exercise time
oints were compared (15 min  post-exercise vs.  pre-exercise:
.94 ± 0.40 vs.  2.04 ± 0.16 pmol/ml, p = 0.012; +4 h post-exercise,
.25 ± 0.22 pmol/ml vs.  pre-exercise: p = 0.196; 4 h post-exercise vs.
5 min  post-exercise:p = 0.093; all Bonferroni-corrected; Fig. 3A).
inally, plasma concentrations of OEA differed only between pre-
xercise and 4 h post-exercise time points (15 min  post-exercise
s. pre-exercise: 6.77 ± 0.45 vs.  6.29 ± 0.33 pmol/ml, p = 0.896; 4 h
ost-exercise, 7.42 ± 0.33 pmol/ml, vs.  pre-exercise: p = 0.001; 4 h
ost-exercise vs.  15 min  post-exercise:p = 0.466; all Bonferroni-
orrected; Fig. 3D).
There were no signiﬁcant main effects of Exercise time point
n plasma concentrations of AEA and PEA (p ≥ 0.058; Table 1 &
ig. 3B,C).
.4. Effects of sleep duration on hunger and stress ratings
In the morning of day 4 following either 3 nights of
hort or normal sleep duration, participants felt hungrier at
:30 a.m. in the short sleep condition than they did in the
ormal sleep condition (+25%, p = 0.034). No other differences
n hunger feelings were observed on day 4 between the
leep duration conditions (F(2.23,33.22) = 2.55, p = 0.088 for Sleep
ondition*Time; F(1.0,15.0) = 0.04, p = 0.843 for Sleep condition;
(2.74,41.08) = 14.94, p < 0.001 for Time; Fig. 4A).
Concerning stress, participants in general felt more stressed
n the normal sleep condition than they did in the short sleep
ondition (F(2.26,33.95) = 0.95, p = 0.407 for Sleep condition*Time;
(1.0,15.0) = 8.57, p = 0.010 for Sleep condition; F(2.47,37.03) = 2.83,
 = 0.061 for Time), especially for ratings done after the physical
xercise task had been completed (i.e., 15 min  post-exercise and
 h post-exercise; Fig. 4B).
When considering individual ratios (i.e., individual values at
ach time points on day 4 in the short sleep condition were divided
y corresponding time-matched individual values in the normal
leep condition, e.g. plasma concentration of 2AG at 8:30 a.m. in
he short sleep condition was divided by plasma concentration
f 2AG at 8:30 a.m. in the normal sleep condition), no correla-
ions were found of subjective hunger and stress ratings with
lasma endocannabinoid concentrations (Pearson’s r (min, max):
AG/AEA/PEA/OEA vs.  hunger, −0.072, 0.027, p ≥ 0.570; vs.  stress,
0.042, 0.159, p ≥ 0.210). condition and Exercise time point → day 4: ∼10 a.m. (last pre-exercise time point),
orrect for sphericity deviations. Abbreviations:  2AG, 2-arachidonoylglycerol; AEA,
de.
4. Discussion
In this study involving 16 healthy young men, we aimed to
investigate if recurrent short sleep duration over three consecutive
nights would alter systemic concentrations of endocannabinoids,
both prior to and following 30 min  of high-intensity ergometer
cycling.
4.1. Comparison with the sleep literature
4.1.1. Effects of sleep restriction on plasma 1/2AG levels
Our study found a rise in plasma 2AG concentrations shortly
after awakening after three nights of short sleep (sleep window
2:45–7 a.m.) vs.  normal sleep (sleep window 22:30 p.m.–7 a.m.).
This is in contrast to results from a recent study involving 14
healthy young adults in which circulating concentrations of 2AG
were found to be primarily increased during afternoon hours
(around 3 p.m.) following four nights of short sleep (sleep win-
dow 1–5:30 a.m.) vs. four nights of normal sleep (sleep window
11 p.m.–7:30 a.m.) (Hanlon et al., 2016). Another ﬁnding in our
study was  that plasma 2AG concentrations in the afternoon (around
3 p.m.) returned to pre-exercise values, an effect that was seen
in both the short and normal sleep condition. This also differs
from recent results demonstrating that plasma 2AG exhibits a
distinct diurnal pattern across a normal sleep-wake cycle, peak-
ing in early-midafternoon (Hanlon et al., 2015). Differences in
meal timing, type of food, duration of fasting, and gender dis-
tribution could offer possible explanations for discrepant results
across experiments, since all of these factors have been shown
to alter endocannabinoid production (Gatta-Cheriﬁ et al., 2012;
Engeli et al., 2014; Kirkham et al., 2002; Blüher et al., 2006; Di
Marzo et al., 2001). Additionally, differences in time awake with
light exposure in the morning (2-h difference in the study by
Hanlon et al. (2016) compared with equal time across our study
conditions), as well as differences in sleep midpoints between
the sleep conditions (3:15 a.m. across both sleep conditions in
Hanlon et al., 2016; 2:45 a.m. and 4:53 a.m. in our normal and par-
tial sleep restriction conditions herein, respectively) may  explain
the differing results observed across these studies. Finally, phys-
ical exercise has been demonstrated to be able to shift circadian
rhythms of both central and peripheral tissues (Schroeder et al.,
2012; Wolff and Esser, 2012). With this in mind, the morning
exercise bout performed in the present study could be the rea-
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Fig. 2. Overnight effects of three nights of either short or normal sleep on plasma concentrations of (A) 2-arachidonoylglycerol (2AG), (B) anandamide (AEA), (C) palmi-
t d dat
4 e poi
s
n
p
w
b
c
2
hoylethanolamide (PEA), and (D) oleoylethanolamide (OEA) before exercise. Analyze
.  *, p < 0.05 for NS vs.  PSD. §,  p < 0.05; and §§§,  p < 0.001 for Bonferroni-corrected tim
on for why plasma 2AG did not peak in the afternoon and did
ot differ between the short and normal sleep conditions at 3
.m.
The increase we observed in plasma 2AG due to sleep restriction
as transient, as it occurred shortly after awakening at 8:30 a.m.,
ut was no longer apparent at 10 a.m. on day 4. Given that endo-
annabinoids are responsive to glucocorticoid hormones (Hill et al.,
010b) and mediate many of the physiological actions of these
ormones in both central and peripheral tissues (Bitencourt et al.,a points are from blood samples taken at 7:30 p.m. on day 3 and at 8:30 a.m. on day
nt comparisons.
2014; Bowles et al., 2015; Hill et al., 2011), an elevated cortisol
awakening response (CAR) following partial sleep loss could rep-
resent a mechanism underlying the transient increase in 2AG at
8:30 a.m. on day 4. Supporting this view, a recent study involving
2751 participants found short sleep duration to be associated with
an increased CAR (Kumari et al., 2009).
Contrary to 8:30 a.m., no differences in plasma 2AG concen-
trations were seen at 10 a.m. (i.e., 3 h after awakening) on day 4
between the sleep conditions. One explanation could be partici-
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Fig. 3. Effects of an acute bout of physical exercise on plasma concentrations of (A) 2-arachidonoylglycerol (2AG), (B) anandamide (AEA), (C) palmitoylethanolamide (PEA),
and  (D) oleoylethanolamide (OEA) following three nights of either short (4.25-h) or normal (8.5-h) sleep duration. Analyzed data are from blood samples collected before
e ol. §,  p
c me po
p
w
r
T
t
l
u
4
l
d
d
ixercise  (∼10 a.m.), as well as 15 min  and 4 h after the end of the exercise protoc
onnected along the horizontal lines below the signiﬁcance symbols indicate the ti
ants’ cumulative bright light exposure with increasing elapsed
akefulness. Light is known to alter the activity of biological clocks
egulating energy and lipid metabolism (Bass and Takahashi, 2010).
hus, it could be hypothesized that possible effects of recurrent par-
ial sleep loss on plasma endocannabinoid concentrations were no
onger modulated by CAR at 10 a.m., but by then mostly driven by
nderlying circadian rhythms.
.1.2. Effects of sleep restriction on plasma AEA, PEA, and OEA
evelsPlasma concentrations of AEA (and its congeners PEA, and OEA)
id not differ between the short and normal sleep duration con-
itions, which is somehow at odds with previous ﬁndings. For
nstance, in a study involving ﬁve healthy humans, circulating < 0.05 and §§§,  p < 0.001 for Bonferroni-corrected time point comparisons; points
ints that are signiﬁcantly different to one another.
AEA concentrations increased from nighttime to morning and then
declined again closer to nighttime when participants were kept
under a normal sleep-wake cycle. In contrast, this pattern was
disrupted following one night of total sleep deprivation (e.g. con-
centrations of plasma AEA did not decline over the day), indicating
that the absence of sleep produces a signiﬁcant dysregulation of cir-
culating AEA (Vaughn et al., 2010). However, others have reported
that total sleep loss did not alter circulating AEA concentrations
(Koethe et al., 2009), whereas they instead found increased levels
of OEA in CSF but not in plasma (Koethe et al., 2009). The latter
ﬁnding is of particular importance for the interpretation of our null
results, as it suggests that the extent by which sleep loss alters
endocannabinoid signaling may  vary across tissues and/or sampled
biological ﬂuids.
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tig. 4. (A) Hunger and (B) stress ratings on the fourth day, following three nights o
eprivation.
.2. Effects of exercise on plasma endocannabinoid
oncentrations
We  found that exercise carried out in the fasted state induced a
hort-term rise (15-min into the recovery period post exercise) in
lasma concentrations of 2AG, whereas no statistically signiﬁcant
ffects on plasma AEA concentrations were found. Similar effects
ave been found after acute psychological stress (Hill et al., 2009).
tudies utilizing acute physical exercise as stressor have however
ound different responses, i.e.,  an increase of plasma concentrations
f AEA but not 2AG (Heyman et al., 2012; Raichlen et al., 2013;
parling et al., 2003). Differences in exercise intensity, circadian
iming of exercise, timing of blood sampling (i.e., during or differ-
nt time points after exercise), and pre-exercise conditions (e.g.
hotic preload, time since last meal, macronutrient composition of
ast meal, and gender distribution) could offer possible explana-
ions for why we observed an increase in plasma concentrationser short sleep or normal sleep duration. *p < 0.05 for normal sleep vs.  partial sleep
of 2AG but not AEA, whereas previous studies found exercise to
increase plasma concentrations of AEA but not 2AG (Heyman et al.,
2012; Raichlen et al., 2013; Sparling et al., 2003). Another consid-
eration when interpreting our data is that a previous study found
plasma 2AG concentrations to increase by around 17% under rest-
ing conditions from 10 a.m. to 11 a.m. (Hanlon et al., 2015), i.e.,
corresponding to the time period during which we  found exer-
cise to elevate plasma concentrations of 2AG. While we observed
an increase much greater (about 44%) than this observed diurnal
ﬂuctuation, the elevated 2AG levels after ergometer cycling may
nevertheless partially have been due to the concurrent natural rise
along its diurnal pattern in blood.
An additional ﬁnding of the present study is that the exercise-
induced rise in plasma concentrations of 2AG did not differ between
sleep conditions. The increase of circulating levels of endocannabi-
noids following exercise has been proposed to partially account for
the anxiolytic (Tantimonaco et al., 2014), anti-nociceptive (Galdino
2 roendo
e
p
i
s
2
p
e
u
b
i
t
o
c
o
i
g
p
c
e
e
b
t
l
r
l
d
4
a
a
r
a
i
n
i
a
(
f
w
f
s
i
e
s
t
i
o
s
i
m
e
e
n
n
c
4
e
n
c
p66 J. Cedernaes et al. / Psychoneu
t al., 2014) and neuroprotective (Hill et al., 2010a) properties of
hysical exercise. Indeed, recent research suggests that at least
n mice, central and peripheral CB1 and CB2 receptors are neces-
ary for inducing anxiolysis and analgesia after running (Fuss et al.,
015). Our results could therefore indirectly suggest that recurrent
artial sleep loss does not alter these centrally acting beneﬁts of
xercise. Importantly however, sleep deprivation may  have mod-
lated post-exercise plasma concentrations of endocannabinoids
efore, in between, or after, the time points measured in our study,
.e.,  15 min  and 4 h after exercise. In light of our ﬁndings that par-
ial sleep loss increased pre-exercise plasma concentrations of 2AG
nly at 8:30 a.m. but not at 10 a.m., differences in plasma endo-
annabinoid concentrations between sleep conditions might have
ccurred if exercise would have been scheduled closer to awaken-
ng.
Finally, an increase of plasma concentrations of OEA (AEA con-
ener) was found at 4 h post-exercise. However, since this rise in
lasma OEA occurred relatively late after physical exercise, this
ould also represent a circadian ﬂuctuation, rather than an exercise
ffect – the circadian proﬁle of this endocannabinoid has how-
ver not yet been properly deﬁned in humans. Since OEA has
een shown to activate peroxisome proliferator-activated recep-
or alpha (PPAR-alpha) (Guzmán et al., 2004), a major regulator of
ipid metabolism that is activated to induce a metabolic adaptive
esponse to prolonged fasting (Kersten et al., 1999), the rise of this
ipid metabolite in plasma could also stem from extended energy
eprivation, exacerbated by the exercise intervention.
.3. Sleep loss increases hunger feelings: possible role of 2AG
A well-known effect of cannabinoids is increased food craving
nd calorie intake (Kirkham, 2009). For instance, intraperitoneal
dministration of rimonabant (an antagonist for the cannabinoid
eceptor CB1) reduces food intake (Thornton-Jones et al., 2006)
nd induces neuronal activation in several hypothalamic nuclei
nvolved in food intake regulation, such as the paraventricular
ucleus (Verty et al., 2009). Furthermore, administration of 2AG
nto the shell of the nucleus accumbens, an extra-hypothalamic
rea strongly linked to eating motivation increases food intake
Kirkham et al., 2002). With these ﬁndings in mind, it could there-
ore be hypothesized that the rise in plasma 2AG (and the sum
ith its isomer 1AG) may  offer a possible molecular mechanism
or ﬁndings of previous studies, which have demonstrated that
leep restriction increases craving and intake of food during morn-
ng hours (Benedict et al., 2012; Cedernaes et al., 2014; Chapman
t al., 2013; Hogenkamp et al., 2013; St-Onge et al., 2011), and pos-
ibly also a reason for the previously observed elevated risk of long
erm weight gain and obesity in those who chronically suffer from
nsufﬁcient sleep (Cappuccio et al., 2008). However, three nights
f partial sleep loss increased plasma concentrations of 2AG only
hortly after awakening in the present study (i.e., 8:30 a.m.), which
s therefore not likely to represent the main mechanism that pro-
otes overeating across 24-h in sleep-deprived people (St-Onge
t al., 2011) – unless it is able to produce a more long-lasting
ffect at the behavioral or energy homeostasis level. Supporting the
otion of a more short-term effect of elevated endocannabinoids,
o correlations were found between plasma endocannabinoid con-
entrations and subjective hunger ratings.
.4. Acute sleep loss reduces subjective stress: possible role of 2AG
An additional observation of our study is that participants gen-
rally felt less stressed following three nights of short sleep vs.
ormal sleep, particularly following the physical exercise proto-
ol. While chronic sleep loss has been associated with increased
sychological stress (Akerstedt, 2006), acute sleep deprivation –crinology 74 (2016) 258–268
foremost total sleep deprivation – has been shown to exert tran-
sient mood-improving effects (Wu  et al., 1999). Given that low
doses of CB1 agonists tend to be anxiolytic and high doses tend to
increase aversion and anxiety-related behaviors (Ganon-Elazar and
Akirav, 2012; also reviewed in Viveros et al., 2005), it could be that
the small but signiﬁcant increase in plasma concentrations of 2AG
shortly after awakening may  have mediated the subjective stress-
reducing effects of short sleep duration. It must however be kept
in mind that we did not ﬁnd any correlations between subjective
stress and plasma concentrations of endocannabinoids. Moreover,
caution is warranted before concluding based on our ﬁndings that
humans can cope better with stressors under conditions of acute
sleep loss. For instance, there is some evidence that humans are
more responsive to the effects of psychological stress when sleep-
deprived compared to when they are well-rested (Cedernaes et al.,
2015b; Minkel et al., 2014). Finally, sleep restriction has also been
shown to promote adverse psychological symptoms (Roy-Byrne
et al., 1986).
5. Conclusions
Given that activation of the endocannabinoid system has been
previously shown to increase acutely appetite and mood (Di Marzo
et al., 2001; Lutz et al., 2015), our results could suggest that behav-
ioral effects of acute sleep loss, such as increased hunger and
transiently improved psychological state, may  partially result from
activation of this signaling pathway. In contrast, exercise-induced
elevations of endocannabinoids appear to be less affected by short
sleep duration. Whether our ﬁndings are generalizable to females,
older participants, or obese humans living under short sleep con-
ditions, or whether similar results would be seen if exercise would
have been carried out following an energy preload, is currently
unknown and would be worth investigating.
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